What's new? Log in Free sign up

GSK (GSK)

Company Profile

Company profile

Ticker

GSK, GLAXF

Exchange

Website

CEO

Emma Natasha Walmsley

Incorporated

Location

Fiscal year end

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Johnson & Johnson • Merck & Co. • AbbVie • Teva Pharmaceutical Industries Limited • Bausch Health Companies • Abbott Laboratories • Eli Lilly and • Bristol-Myers Squibb • Viatris ...

Former names

GLAXOSMITHKLINE PLC

SEC CIK

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Material Contracts & Credit Agreements

Subsidiaries Lists

GSK stock data

1M 3M 6M 1Y

Latest filings (excl ownership)

View all

Transaction In Own Shares

Transaction In Own Shares

Transaction In Own Shares

Transaction In Own Shares

Transaction In Own Shares

Transaction In Own Shares

Director/pdmr Shareholding

Total Voting Rights

Transaction In Own Shares

Transaction In Own Shares

Transcripts

View all

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Latest ownership filings

View all

Annual report of employee stock purchases

Annual report of employee stock purchases

Spero Therapeutics, Inc.

BlackRock, Inc.

23andMe Holding Co.

GSK / GSK ownership change

Wave Life Sciences Ltd.

Annual report of employee stock purchases

Financial summary

Financial statements Chart GSK financial data

Quarter (USD)	Dec 24	Dec 23	Dec 22	Dec 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 24	Dec 23	Dec 22	Dec 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from GSK earnings reports.

Institutional ownership, Q4 2024

GSK institutional ownership history Ownership history

18.2% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	1	0	NEW
Opened positions	1	0	NEW
Closed positions	0	0
Increased positions	0	0
Reduced positions	0	0

13F shares	Current	Prev Q	Change
Total value	13.07 bn	0.00	NEW
Total shares	369.58 mm	0.00	NEW
Total puts	0.00	0.00
Total calls	0.00	0.00
Total put/call ratio	–	–	–

Largest owners	Shares	Value	Change
BlackRock	369.58 mm	$13.07 bn	NEW

Largest transactions	Shares	Bought/sold	Change
BlackRock	369.58 mm	+369.58 mm	NEW

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

GSK insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
27 Sep 24	GSK	Ordinary Shares	Buy	Acquire P	Yes	No	8	2,791,930	22.34 mm	16,775,691

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

News

From Benzinga Pro

On December 4, 2025 GSK Terminated Collaboration With IDEAYA Biosciences; GSK Will Transfer The Werner Helicase And Pol Theta Clinical Programs To The Co In Accordance With The Applicable Provisions Of The Agreement; IDEAYA Biosciences Will Evaluate Its Strategic Options For These Two Programs In 2026, And The Update Does Not Change Its Expectation Of Cash Runway Into 2030

On December 4, 2025, GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 4) ("GSK") communicated to IDEAYA Biosciences, Inc. (the "Company") its election to terminate the Collaboration, Option and License Agreement, dated

Is GSK PLC Gaining or Losing Market Support?

CDC Prevention Advisory Committee On Immunization Practices Voted To Abandon Universal Hepatitis B Vaccination For Newborns

https://www.cnn.com/health/live-news/cdc-vaccine-meeting-hepatitis-b-12-05-25

AstraZeneca, GSK Among Executives Asked To Help Redesign UK Pricing Rules-Report

Trump Administration Locks In Zero Tariffs On UK Pharmaceuticals As NHS To Pay More For US Drugs

Press releases

From Benzinga Pro

Blenrep approved by US FDA for use in treatment of relapsed/refractory multiple myeloma

Significant unmet need for patients requires new and novel treatments1 DREAMM-7 showed a 51% reduction in the risk of death and tripled median progression-free survival in 3L+ indicated population versus a

PIVOT-PO Phase 3 Data Show Tebipenem HBr's Potential as the First Oral Carbapenem Antibiotic for Patients with Complicated Urinary Tract Infections (cUTIs)

Data presented at IDWeek 2025 after study stopped early for efficacyPrimary endpoint met, demonstrating non-inferiority of oral tebipenem HBr compared to intravenous treatment1Data will be shared with regulatory

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.